SNWV Pengajuan SEC - SANUWAVE Health, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1417663

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to SANUWAVE Health, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 22, 2025	EX-FILING FEES	Calculation of Filing Fee Table Form S-8 (Form Type) SANUWAVE Health, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) SANUWAVE Health, Inc.
August 22, 2025	S-8	As filed with the Securities and Exchange Commission on August 22, 2025 As filed with the Securities and Exchange Commission on August 22, 2025 Registration No.
August 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 21, 2025 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 001-42552 20-1176000 (State or other jurisdiction of incorporation) (Commission File
August 20, 2025	EX-10.1	SANUWAVE HEALTH, INC. 2024 EQUITY INCENTIVE PLAN (As Amended August 19, 2025) SANUWAVE HEALTH, INC. 2024 EQUITY INCENTIVE PLAN (As Amended August 19, 2025) 1.Purpose. The purpose of the SANUWAVE Health, Inc. 2024 Equity Incentive Plan (the “Plan”) is to attract and retain the best available personnel for positions of responsibility with the Company, to provide additional incentives to them and align their interests with those of the Company’s stockholders, and to thereby pr
August 20, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 19, 2025 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 001-42552 20-1176000 (State or other jurisdiction of incorporation) (Commission File
August 8, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2025 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission Fil
August 8, 2025	EX-99.1	Sanuwave Announces Q2 FY2025 Financial Results Q2 2025 revenues were $10.2 million, up 42% from $7.2 million in Q2 2024. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 gross margin was 78.3%, versus 73.2% in Q2 2024. GA Exhibit 99.1 Sanuwave Announces Q2 FY2025 Financial Results Q2 2025 revenues were $10.2 million, up 42% from $7.2 million in Q2 2024. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 gross margin was 78.3%, versus 73.2% in Q2 2024. GAAP Operating Income was $1.9 million for Q2 2025 versus $2.0 million in Q2 2024. Q2 2025 included equity compensation costs of $1.1 milli
August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-52
July 31, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 28, 2025 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 001-42552 20-1176000 (State or other jurisdiction of incorporation) (Commission File N
July 31, 2025	EX-10.1	SEPARATION AND RELEASE AGREEMENT Exhibit 10.1 SEPARATION AND RELEASE AGREEMENT Background I.I Nanci Gilmore was employed by SANUWAVE (as defined below) until my employment was terminated involuntarily without cause effective 5/30/2025 (my “Separation Date”). II.SANUWAVE has offered to provide me certain Consideration (as defined below) subject to the terms and conditions of this Separation and Release Agreement (“Release”). III.I
July 14, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 14, 2025 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File N
July 14, 2025	EX-99.1	SANUWAVE Health Announces Preliminary Revenue Results for the Second Quarter 2025 (Ended June 30, 2025) Exhibit 99.1 SANUWAVE Health Announces Preliminary Revenue Results for the Second Quarter 2025 (Ended June 30, 2025) Sanuwave is pleased to announce preliminary revenues of $10.1 million to $10.2 million for the second quarter ended June 30, 2025. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 revenue increased between 41% and 42% compared to Q2 2024. First half of 2
July 10, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commis
July 10, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14a
June 26, 2025	8-K	Other Events 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 26, 2025 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File
June 3, 2025	EX-10.1	January 11, 2023 Exhibit 10.1 January 11, 2023 Nanci Gilmore Via email: [***] Dear Nanci: SANUWAVE, Inc. (the “Company”) is pleased to extend to you this conditional offer of employment as Vice President Commercial Strategy, Wound Care reporting directly to the Chief Executive Officer. We anticipate your start date will be on February 1, 2023, or such earlier date as you are released from your current employment o
June 3, 2025	EX-99.1	Sanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial Operations Exhibit 99.1 Sanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial Operations Sanuwave Health, Inc. June 3, 2025 Libby brings strong team building, growth, and sales operations and systems skills to Sanuwave after a career of growing start ups into mid and large sized companies. EDEN PRAIRIE, MN, June 3, 2025 (GLOBE NEWSWIRE) – Sanuwave Health, Inc. (the
June 3, 2025	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 30, 2025 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File
May 30, 2025	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 11495 Valley View Road, Eden Prairie, Minnesota 55344 (Address of principal e
May 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 26, 2025 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File
May 21, 2025	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 12, 2025 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation)
May 15, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 12, 2025 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File
May 15, 2025	EX-16.1	May 15, 2025 Exhibit 16.1 May 15, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by SANUWAVE Health, Inc. under Item 4.01 of its Form 8-K dated May 15, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of SANUWAVE Health, Inc. contained ther
May 9, 2025	EX-99.1	Sanuwave Announces Q1 FY2025 Financial Results Q1 2025 revenues were $9.3 million, up 61% from $5.8 million in Q1 2024. This represents the highest Q1 quarterly revenues in Company history. Q1 2025 gross margin was 79.0%, versus 72.6% in Q1 2024. GAA Exhibit 99.1 Sanuwave Announces Q1 FY2025 Financial Results Q1 2025 revenues were $9.3 million, up 61% from $5.8 million in Q1 2024. This represents the highest Q1 quarterly revenues in Company history. Q1 2025 gross margin was 79.0%, versus 72.6% in Q1 2024. GAAP Operating Income was $1.0 million for Q1 2025, an increase of $2.0 million from Q1 2024. Company provides guidance for revenue growth o
May 9, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 9, 2025 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File N
May 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-5
April 14, 2025	EX-16.1	April 14, 2025 Exhibit 16.1 April 14, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by SANUWAVE Health, Inc. under Item 4.01 of its Form 8-K dated April 14, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of SANUWAVE Health, Inc. contained
April 14, 2025	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 10, 2025 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File
April 8, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 8, 2025 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File N
April 8, 2025	EX-99.1	SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025) SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025) SANUWAVE is pleased to announce preliminary revenues of $9.
March 31, 2025	EX-10.1	Lease, effective as of March 27, 2025, between Sanuwave, Inc. and Henry Kumagai, Trustee of the Kumagai Family Trust U/A Dated May 11, 2010 (Incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on March 31, 2025). Exhibit 10.1 LEASE This LEASE (“Lease”) is made and entered into as of March 27, 2025 (the, “Effective Date”), by and between HENRY KUMAGAI, TRUSTEE OF THE KUMAGAI FAMILY TRUST U/A DATED MAY 11, 2010 (“Landlord”) and SANUWAVE, INC., a Delaware corporation (“Tenant”). RECITALS A.Landlord is the owner of the real estate located at 9600 West 76th Street, Eden Prairie, MN 55344 (the “Real Estate”). Th
March 31, 2025	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) 3/27/2025 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File Numbe
March 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 21, 2025 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File
March 21, 2025	EX-99.1	SANUWAVE Announces Record Quarterly Revenues: Q4 FY2024 Financial Results Q4 2024 revenues were $10.3 million, up 47% from Q4 2023. This was an all-time quarterly record for the Company. Full year 2024 revenues were $32.6 million up 60% from full yea Exhibit 99.1 SANUWAVE Announces Record Quarterly Revenues: Q4 FY2024 Financial Results Q4 2024 revenues were $10.3 million, up 47% from Q4 2023. This was an all-time quarterly record for the Company. Full year 2024 revenues were $32.6 million up 60% from full year 2023 revenues. This was an all-time annual record for the Company. Q4 2024 gross margin was 77.9%, versus 69.1% in Q4 2023 and 75.5% in
March 20, 2025	EX-19.1	SANUWAVE Health, Inc. Insider Trading Policy. SANUWAVE HEALTH, INC. INSIDER TRADING POLICY Adopted: December 27, 2024 Federal and state securities laws prohibit individuals from trading in the securities of a company while they are aware of material information about that company that is not generally known or available to the public. Such trading is often referred to as “insider trading.” The purpose of this Insider Trading Policy (this “Pol
March 20, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to.
March 20, 2025	EX-97.1	SANUWAVE Health, Inc. Compensation Recovery Policy. SANUWAVE HEALTH, INC. COMPENSATION RECOVERY POLICY Effective March 4, 2025 Policy The Board of Directors (the “Board”) of Sanuwave Health, Inc. (the “Company”) has adopted this Compensation Recovery Policy (this “Policy”) pursuant to Rule 10D-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Securities and Exchange Commission (the “SEC”) regulations promulgated thereun
March 7, 2025	EX-3.1	Amended and Restated Bylaws (Incorporated by reference to Exhibit 3. Exhibit 3.1 AMENDED AND RESTATED BYLAWS SANUWAVE HEALTH, INC. a Nevada corporation ARTICLE I OFFICES Section 1.1 Principal Office. The principal office and place of business of Sanuwave Health, Inc. (the “Corporation”) shall be at 11495 Valley View Road, Eden Prairie, MN 55344, or at such other location as established from time to time by resolution of the board of directors of the Corporation (th
March 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 3, 2025 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File N
March 7, 2025	EX-99.1	Sanuwave Health to Uplist to the Nasdaq Global Market Trading Under the Ticker “SNWV” Expected to Begin on March 7, 2025 Sanuwave Health to Uplist to the Nasdaq Global Market Trading Under the Ticker “SNWV” Expected to Begin on March 7, 2025 EDEN PRAIRIE, MN, March 4, 2025 (GLOBE NEWSWIRE) - Sanuwave Health, Inc.
March 6, 2025	8-A12B	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 20-1176000 (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) 11495 Valley Vie
January 15, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 13, 2025 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission Fil
January 15, 2025	EX-10.1	Separation and Release Agreement, dated January 13, 2025, between Timothy Hendricks and the Company (Incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on January 15, 2025). Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL SEPARATION AND RELEASE AGREEMENT Background I. I (Tim Hendricks) was employed by SANUWAVE (as defined below) pursuant to the terms of the Employment Agreement dated January 17, 2023 (the “Em
January 14, 2025	EX-99	SANUWAVE Announces Preliminary Revenue Results for the Fourth Quarter 2024 (Ended December 31, 2024) Exhibit 99.1 SANUWAVE Announces Preliminary Revenue Results for the Fourth Quarter 2024 (Ended December 31, 2024) Sanuwave is pleased to announce preliminary revenues of $10.1 million to $10.3 million for the fourth quarter ended December 31, 2024. This represents the highest quarterly revenues in company history. Q4 2024 revenue increased between 44% and 47% compared to Q4 2023. UltraMist revenue
January 14, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 13, 2025 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission Fil
January 10, 2025	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 3, 2025 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File
December 17, 2024	CORRESP	SANUWAVE Health, Inc. 11495 Valley View Road Eden Prairie, Minnesota 55344 SANUWAVE Health, Inc. 11495 Valley View Road Eden Prairie, Minnesota 55344 December 17, 2024 VIA EDGAR TRANSMISSION Division of Corporation Finance Office of Industrial Applications and Services United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: SANUWAVE Health, Inc. Registration Statement on Form S-1 (Registration No. 333-283576) Request for Acceleratio
December 3, 2024	S-1	As filed with the Securities and Exchange Commission on December 3, 2024 As filed with the Securities and Exchange Commission on December 3, 2024 Registration No.
December 3, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) SANUWAVE Health, Inc.
November 13, 2024	EX-10.2	Amendment to Stock Option Agreement, dated as of November 12, 2024, by and between the Company and Kevin A. Richardson, II (Incorporated by reference to Exhibit 10.2 to the Form 8-K filed with the SEC on November 13, 2024). Exhibit 10.2 SANUWAVE HEALTH, INC. 2024 EQUITY INCENTIVE PLAN Amendment to Stock Option Agreement This Amendment (the “Amendment”), made and entered into as of November 12, 2024, by and between SANUWAVE Health, Inc. (the “Company”) and Kevin Richardson, II (the "Participant"), amends the terms and conditions of a certain award agreement governing the terms of stock options granted under the Plan (
November 13, 2024	EX-10.1	Acknowledgment and Mutual Agreement, effective as of November 12, 2024, by and between the Company and Kevin A. Richardson, II (Incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on November 13, 2024). Exhibit 10.1 ACKNOWLEDGMENT AND MUTUAL AGREEMENT This Acknowledgment and Mutual Agreement (“Acknowledgment”) is entered into by and between Kevin Richardson, II (“Richardson”) and SANUWAVE Health, Inc. (“SANUWAVE” together with its affiliates, the “Company”), effective as of November 12, 2024 (“Effective Date”). BACKGROUND A.Richardson and SANUWAVE entered into a Transition and Separation Agreemen
November 13, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 12, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission Fi
November 8, 2024	EX-99.1	SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results Q3 2024 revenues were $9.4 million, up 89% from Q3 2023. This was an all-time quarterly record for the Company. Q3 2024 gross margin was 75.5%, vs 71.5% in Q3 2023 GAAP Operati Exhibit 99.1 SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results Q3 2024 revenues were $9.4 million, up 89% from Q3 2023. This was an all-time quarterly record for the Company. Q3 2024 gross margin was 75.5%, vs 71.5% in Q3 2023 GAAP Operating Income was $2.0 million Company provides guidance for revenue growth of 40-50% for Q4 2024 versus Q4 2023 EDEN PRAIRIE, MN, November 8
November 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 8, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission Fil
November 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0
October 25, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 22, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission Fil
October 25, 2024	EX-10.1	Form of Stock Option Award Agreement under the SANUWAVE Health, Inc. 2024 Equity Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on October 25, 2024). Exhibit 10.1 SANUWAVE HEALTH, INC. 2024 EQUITY INCENTIVE PLAN Stock Option Agreement Grant Notice SANUWAVE Health, Inc. (the “Company”), pursuant to its 2024 Equity Incentive Plan (the “Plan”), hereby grants an option to purchase the number of Shares set forth below (the “Option”) to you, the Participant named below. The terms and conditions of this Option award (this “Award”) are set forth in thi
October 22, 2024	SC 13G/A	SNWVD / SANUWAVE Health, Inc. / Opaleye Management Inc. Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Sanuwave Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 80303D305 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108 (Name, Address and Telepho
October 22, 2024	SC 13D/A	SNWV / SANUWAVE Health, Inc. / MANCHESTER MANAGEMENT CO LLC Activist Investment SC 13D/A 1 d1150656213d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 10)* Sanuwave Health, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 80303D107 (CUSIP Number) James E. Besser c/o Manchester Management Company, LLC 2 Calle Candina, #1701 San Juan, Puerto Rico, 0090
October 18, 2024	EX-10.3	Registration Rights Agreement, dated October 16, 2024, by and among the Company and the purchasers identified on the signature pages thereto (Incorporated by reference to Exhibit 10.3 to the Form 8-K filed with the SEC on October 18, 2024). Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of October 16, 2024 (the “Agreement Date”), by and between SANUWAVE Health, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursua
October 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 15, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission Fil
October 18, 2024	EX-10.2	Securities Purchase Agreement, dated October 16, 2024, by and among the Company and the purchasers identified on the signature pages thereto (Incorporated by reference to Exhibit 10.2 to the Form 8-K filed with the SEC on October 18, 2024). Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 16, 2024 (the “Agreement Date”), between SANUWAVE Health, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to th
October 18, 2024	EX-99.1	Sanuwave Health Announces 1-For-375 Reverse Stock Split - Common stock will begin trading on a split-adjusted basis on October 18, 2024 - Exhibit 99.1 Sanuwave Health Announces 1-For-375 Reverse Stock Split - Common stock will begin trading on a split-adjusted basis on October 18, 2024 - EDEN PRAIRIE, MN, October 16, 2024 - via NewMediaWire - Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that, effective at 12:01 a.m. Mountain
October 18, 2024	S-8 POS	As filed with the Securities and Exchange Commission on October 18, 2024 As filed with the Securities and Exchange Commission on October 18, 2024 Registration No.
October 18, 2024	EX-3.1	Certificate of Amendment of the Articles of Incorporation, effective as of October 18, 2024 (Incorporated by reference to Exhibit 3.1 to the Form 8-K filed with the SEC on October 18, 2024). PAGE 3 TO THE CERTIFICATE OF AMENDMENT ARTICLES OF INCORPORATION SANUWAVE HEALTH, INC.
October 18, 2024	EX-FILING FEES	Calculation of Filing Fee Table FORM S-8 (Form Type) SANUWAVE Health, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) SANUWAVE Health, Inc.
October 18, 2024	EX-10.1	, 2024, by and among NH Expansion Credit Fund Holdings LP, as agent, the noteholders party thereto, and the Company (Incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on October 1 Exhibit 10.1 CONSENT AND LIMITED WAIVER TO NOTE AND WARRANT PURCHASE AND SECURITY AGREEMENT This Consent and Limited Waiver to Note and Warrant Purchase and Security Agreement (this “Consent”) is entered into as of October 17, 2024, by and among NH EXPANSION CREDIT FUND HOLDINGS LP (“North Haven Expansion”), as agent (in such capacity, together with its successors or permitted assigns, “Agent”), t
October 18, 2024	S-8	As filed with the Securities and Exchange Commission on October 18, 2024 As filed with the Securities and Exchange Commission on October 18, 2024 Registration No.
October 18, 2024	EX-99.2	SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering 1-for-375 reverse stock split effective at market open today Exchanged $43.2 million in principal amount of convertible notes and warrants previously exercisable for Exhibit 99.2 SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering 1-for-375 reverse stock split effective at market open today Exchanged $43.2 million in principal amount of convertible notes and warrants previously exercisable for approximately 1.7 billion pre-split shares for approximately 4.0 million post-split shares Closed $10.3 million equity only PIPE offerin
August 13, 2024	EX-99.1	SANUWAVE Announces Record Quarterly Revenues: Q2 FY2024 Financial Results Exhibit 99.1 SANUWAVE Announces Record Quarterly Revenues: Q2 FY2024 Financial Results Q2 2024 revenues were $7.2 million, up 53% from Q2 2023. This was an all-time quarterly record for the Company. Q2 2024 gross margin was 73%, vs 74% in Q2 2023 GAAP Operating Income was $2.0 million Company provides guidance for revenue growth of 65-75% for Q3 2024 versus Q3 2023 EDEN PRAIRIE, MN, August 13, 202
August 13, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 13, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File
August 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-52
August 9, 2024	EX-10.1	SANUWAVE Health, Inc. 2024 Equity Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on August 9, 2024). Exhibit 10.1 SANUWAVE HEALTH, INC. 2024 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the SANUWAVE Health, Inc. 2024 Equity Incentive Plan (the “Plan”) is to attract and retain the best available personnel for positions of responsibility with the Company, to provide additional incentives to them and align their interests with those of the Company’s stockholders, and to thereby promote the Compa
August 9, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File
July 18, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14a
July 17, 2024	EX-10.1	Sixth Amendment to Note and Warrant Purchase and Security Agreement, dated as of July 15, 2024, by and among NH Expansion Credit Fund Holdings LP, as agent, the noteholders party thereto, and the Company (Incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on July 17, 2024). Exhibit 10.1 SIXTH AMENDMENT TO NOTE AND WARRANT PURCHASE AND SECURITY AGREEMENT This Sixth Amendment to Note and Warrant Purchase and Security Agreement (this “Amendment”) is entered into as of July 15, 2024, by and among NH EXPANSION CREDIT FUND HOLDINGS LP (“North Haven Expansion”), as agent (in such capacity, together with its successors or permitted assigns, “Agent”), the Holders from time to
July 17, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 15, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File N
July 10, 2024	EX-99.1	SANUWAVE Health Announces Preliminary Revenue Results for the Second Quarter 2024 (Ended June 30, 2024) Exhibit 99.1 SANUWAVE Health Announces Preliminary Revenue Results for the Second Quarter 2024 (Ended June 30, 2024) SANUWAVE is pleased to announce preliminary revenues of $7.0 million to $7.2 million for the second quarter ended June 30, 2024. This represents the highest quarterly revenues in company history. Q1 2024 revenue increased between 50% and 54% compared to Q2 2023. UltraMist revenues f
July 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 10, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File N
July 8, 2024	PRE 14A	PRELIMINARY COPY DATED JULY 8, 2024, SUBJECT TO COMPLETION PRELIMINARY COPY DATED JULY 8, 2024, SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 26, 2024	EX-99.1	Sanuwave Announces Termination of Merger Agreement with SEP Acquisition Corp. Exhibit 99.1 Sanuwave Announces Termination of Merger Agreement with SEP Acquisition Corp. Company to pursue alternate plans for capital structure improvement including a proposed reverse stock split and a note and warrant exchange independent of a merger transaction EDEN PRAIRIE, MN, June 26, 2024 (GLOBE NEWSWIRE) - via NewMediaWire - Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (OTCQB: SN
June 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 25, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File N
June 24, 2024	SC 13D/A	SNWV / SANUWAVE Health, Inc. / MANCHESTER MANAGEMENT CO LLC Activist Investment SC 13D/A 1 d11065416.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 9)* Sanuwave Health, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 80303D107 (CUSIP Number) James E. Besser c/o Manchester Management Company, LLC 2 Calle Candina, #1701 San Juan, Puerto Rico, 00907 Tele
June 21, 2024	EX-4.2	PROMISSORY NOTE SANUWAVE HEALTH, INC. Exhibit 4.2 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATES IN THE UNITED STATES. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. TH
June 21, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 18, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File N
June 21, 2024	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 18, 2024, by and between SANUWAVE Health, Inc., a corporation organized under the laws of Nevada (the “Company”), and the purchasers identified on the signature pages hereto (including their successors and permitted assigns, the “Purchasers,” and each, a “Purchaser”). WHEREAS, subje
June 21, 2024	EX-10.3	Subordination Agreement, dated June 18, 2024, by and among the Company, NH Expansion Credit Fund Holdings LP and certain creditors (Incorporated by reference to Exhibit 10.3 to the Form 8-K filed with the SEC on June 21, 2024). Exhibit 10.3 SUBORDINATION AGREEMENT This SUBORDINATION AGREEMENT, dated as of June 18, 2024, is between NH EXPANSION CREDIT FUND HOLDINGS LP (“North Haven Expansion”), as agent for the Holders (as hereafter defined; in such capacity, together with its successors or permitted assigns, “Agent”), and the creditors set forth on the signature pages hereto (“Creditors”). R E C I T A L S A. SANUWAVE HEA
June 21, 2024	EX-4.1	SANUWAVE HEALTH, INC. FUTURE ADVANCE CONVERTIBLE PROMISSORY NOTE Exhibit 4.1 THE INDEBTEDNESS EVIDENCED BY THIS NOTE (AS DEFINED BELOW) IS SUBORDINATE TO THE INDEBTEDNESS OF SANUWAVE HEALTH, INC. (OR ANY SUCCESSOR THERETO) TO NH EXPANSION CREDIT FUND HOLDINGS LP, TO THE EXTENT AND PURSUANT TO THE TERMS OF THAT CERTAIN SUBORDINATION AGREEMENT, DATED AS OF JUNE 18, 2024, BY AND AMONG NH EXPANSION CREDIT FUND HOLDINGS LP AND THE PARTIES IDENTIFIED ON THE SIGNATURE
June 21, 2024	EX-4.2	PROMISSORY NOTE SANUWAVE HEALTH, INC. Exhibit 4.2 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATES IN THE UNITED STATES. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. TH
June 21, 2024	EX-10.2	Security Agreement, dated June 18, 2024, by and among the Company and certain lenders (Incorporated by reference to Exhibit 10.2 to the Form 8-K filed with the SEC on June 21, 2024). Exhibit 10.2 SECURITY AGREEMENT THIS SECURITY AGREEMENT dated as of June 18, 2024 (this “Agreement”), is made by SANUWAVE Health, Inc., a corporation organized under the laws of Nevada (the “Borrower”), having an address of 11495 Valley View Road, Eden Prairie, MN 55344, in favor of the lenders set forth on the signature pages hereto (together with their successors and permitted assigns, the “Lend
June 21, 2024	EX-10.5	SANUWAVE HEALTH, INC. Waiver Letter Exhibit 10.5 SANUWAVE HEALTH, INC. Waiver Letter The undersigned is the holder of certain securities of SANUWAVE Health, Inc. (the “Company”) issued on June 18, 2024, including a Future Advance Convertible Promissory Note (the “Note”) and Common Stock Purchase Warrants, one of which has an exercise price of $0.067 per share of the Company’s common stock, par value $0.001 per share (the “Common Sto
June 21, 2024	EX-10.6	Form of Letter Agreement with purchasers in June 2024 offering (Incorporated by reference to Exhibit 10.6 to the Form 8-K filed with the SEC on June 21, 2024). Exhibit 10.6 June 18, 2024 Greetings, We hope this communication finds you well. We are writing because you are a holder of certain outstanding Sanuwave notes and warrants issued in June 2024 and as you have likely seen Sanuwave has announced its intent to merge into a subsidiary of SEP Acquisition Corporation (SEPA) in order to become a national securities exchange traded company and as a means t
June 21, 2024	EX-10.1	Securities Purchase Agreement, dated June 18, 2024, by and among the Company and the purchasers identified on the signature pages thereto (Incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on June 21, 2024). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 18, 2024, by and between SANUWAVE Health, Inc., a corporation organized under the laws of Nevada (the “Company”), and the purchasers identified on the signature pages hereto (including their successors and permitted assigns, the “Purchasers,” and each, a “Purchaser”). WHEREAS, subje
June 21, 2024	EX-4.3	COMMON STOCK PURCHASE WARRANT SANUWAVE HEALTH, INC. Exhibit 4.3 COMMON STOCK PURCHASE WARRANT SANUWAVE HEALTH, INC. Warrant Shares: [•] Initial Exercise Date: June 18, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [•] or [its/their] assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date here
June 21, 2024	EX-10.4	Registration Rights Agreement, dated June 18, 2024, by and among the Company and certain lenders (Incorporated by reference to Exhibit 10.4 to the Form 8-K filed with the SEC on June 21, 2024). Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of June 18, 2024 (the “Closing Date”), by and among SANUWAVE Health, Inc., a Nevada corporation (the “Company”), and each lender identified on the signature pages hereto (including their successors and assigns, the “Lenders,” and each, a “Lender”). RECITALS WHEREAS, the Company and the Lende
June 21, 2024	EX-10.3	SUBORDINATION AGREEMENT Exhibit 10.3 SUBORDINATION AGREEMENT This SUBORDINATION AGREEMENT, dated as of June 18, 2024, is between NH EXPANSION CREDIT FUND HOLDINGS LP (“North Haven Expansion”), as agent for the Holders (as hereafter defined; in such capacity, together with its successors or permitted assigns, “Agent”), and the creditors set forth on the signature pages hereto (“Creditors”). R E C I T A L S A. SANUWAVE HEA
June 21, 2024	EX-4.1	SANUWAVE HEALTH, INC. FUTURE ADVANCE CONVERTIBLE PROMISSORY NOTE Exhibit 4.1 THE INDEBTEDNESS EVIDENCED BY THIS NOTE (AS DEFINED BELOW) IS SUBORDINATE TO THE INDEBTEDNESS OF SANUWAVE HEALTH, INC. (OR ANY SUCCESSOR THERETO) TO NH EXPANSION CREDIT FUND HOLDINGS LP, TO THE EXTENT AND PURSUANT TO THE TERMS OF THAT CERTAIN SUBORDINATION AGREEMENT, DATED AS OF JUNE 18, 2024, BY AND AMONG NH EXPANSION CREDIT FUND HOLDINGS LP AND THE PARTIES IDENTIFIED ON THE SIGNATURE
June 21, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 18, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File N
June 21, 2024	EX-10.6	**** Exhibit 10.6 June 18, 2024 Greetings, We hope this communication finds you well. We are writing because you are a holder of certain outstanding Sanuwave notes and warrants issued in June 2024 and as you have likely seen Sanuwave has announced its intent to merge into a subsidiary of SEP Acquisition Corporation (SEPA) in order to become a national securities exchange traded company and as a means t
June 21, 2024	EX-10.5	Form of Waiver Letter with purchasers in June 2024 offering (Incorporated by reference to Exhibit 10.5 to the Form 8-K filed with the SEC on June 21, 2024). Exhibit 10.5 SANUWAVE HEALTH, INC. Waiver Letter The undersigned is the holder of certain securities of SANUWAVE Health, Inc. (the “Company”) issued on June 18, 2024, including a Future Advance Convertible Promissory Note (the “Note”) and Common Stock Purchase Warrants, one of which has an exercise price of $0.067 per share of the Company’s common stock, par value $0.001 per share (the “Common Sto
June 21, 2024	EX-4.3	COMMON STOCK PURCHASE WARRANT SANUWAVE HEALTH, INC. Exhibit 4.3 COMMON STOCK PURCHASE WARRANT SANUWAVE HEALTH, INC. Warrant Shares: [•] Initial Exercise Date: June 18, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [•] or [its/their] assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date here
June 21, 2024	EX-10.4	REGISTRATION RIGHTS AGREEMENT Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of June 18, 2024 (the “Closing Date”), by and among SANUWAVE Health, Inc., a Nevada corporation (the “Company”), and each lender identified on the signature pages hereto (including their successors and assigns, the “Lenders,” and each, a “Lender”). RECITALS WHEREAS, the Company and the Lende
June 21, 2024	EX-10.2	SECURITY AGREEMENT Exhibit 10.2 SECURITY AGREEMENT THIS SECURITY AGREEMENT dated as of June 18, 2024 (this “Agreement”), is made by SANUWAVE Health, Inc., a corporation organized under the laws of Nevada (the “Borrower”), having an address of 11495 Valley View Road, Eden Prairie, MN 55344, in favor of the lenders set forth on the signature pages hereto (together with their successors and permitted assigns, the “Lend
June 4, 2024	EX-99.1	Sanuwave Provides Corporate Update Exhibit 99.1 Sanuwave Provides Corporate Update Sanuwave pays off $6.3 million Celularity note and interest for $2.075 million SEPA merger outside date to be extended to June 30, 2024 Combined entity has applied to list on Cboe BZX Exchange, Inc. EDEN PRAIRIE, MN, June 4, 2024 (GLOBE NEWSWIRE) - via NewMediaWire - Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (OTCQB: SNWV), a leading provide
June 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File Nu
June 4, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File Nu
June 3, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 28, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File Nu
June 3, 2024	EX-2.1	Amended Number Three to Agreement and Plan of Merger, dated as of May 28, 2024, by and between SEP Acquisition Corp. and SANUWAVE Health, Inc. (Incorporated by reference to Exhibit 2.1 to the Form 8-K filed with the SEC on June 3, 2024). Exhibit 2.1 AMENDMENT NUMBER THREE TO AGREEMENT AND PLAN OF MERGER THIS AMENDMENT NUMBER THREE TO AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated as of May 28, 2024, is by and between (i) SEP Acquisition Corp., a Delaware corporation (the “Purchaser”), and (ii) SANUWAVE Health, Inc., a Nevada corporation (the “Company”). RECITALS WHEREAS, Purchaser, SEP Acquisition Holdings Inc., a Nevada c
June 3, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 28, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File Nu
June 3, 2024	EX-2.1	AMENDMENT NUMBER THREE TO AGREEMENT AND PLAN OF MERGER Exhibit 2.1 AMENDMENT NUMBER THREE TO AGREEMENT AND PLAN OF MERGER THIS AMENDMENT NUMBER THREE TO AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated as of May 28, 2024, is by and between (i) SEP Acquisition Corp., a Delaware corporation (the “Purchaser”), and (ii) SANUWAVE Health, Inc., a Nevada corporation (the “Company”). RECITALS WHEREAS, Purchaser, SEP Acquisition Holdings Inc., a Nevada c
May 10, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 10, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File Nu
May 10, 2024	EX-99.1	SANUWAVE Announces Q1 FY2024 Financial Results Exhibit 99.1 SANUWAVE Announces Q1 FY2024 Financial Results Q1 2024 revenues were $5.8 million, up 53% from Q1 2023 Q1 2024 gross margin was 73%, up 600bp from Q1 2023 Operating loss was $1.1 million for Q1 2024 compared to $2.0 million for Q1 2023 Company provides guidance for revenue growth of 45-55% for Q2 2024 versus Q2 2023 and reiterates revenue growth guidance of 50% for FY 2024 compared to
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-52985 SANUWAVE Heal
April 26, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 25, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File
April 26, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 25, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File
April 26, 2024	EX-10.1	Amendment Number Two to Agreement and Plan of Merger, dated as of April 25, 2024, by and between SEP Acquisition Corp. and SANUWAVE Health, Inc. (Incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on April 26, 2024). Exhibit 10.1 Execution Version AMENDMENT NUMBER TWO TO AGREEMENT AND PLAN OF MERGER THIS AMENDMENT NUMBER TWO TO AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated as of April 25, 2024, is by and between (i) SEP Acquisition Corp., a Delaware corporation (the “Purchaser”), and (ii) SANUWAVE Health, Inc., a Nevada corporation (the “Company”). RECITALS WHEREAS, Purchaser, SEP Acquisition Holdings
April 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 10, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File
April 10, 2024	EX-99.1	SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2024 (Ended March 31, 2024) Exhibit 99.1 SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2024 (Ended March 31, 2024) SANUWAVE is pleased to announce preliminary revenues of $5.7 million to $5.9 million for the first quarter ended March 31, 2024. This represents the highest Q1 revenues in company history. Q1 2024 revenue increased between 51% and 56% compared to Q1 2023. UltraMist revenues for Q1 2
April 1, 2024	EX-10.2	Offer Letter of Peter Sorensen, dated March 26, 2024 (Incorporated by reference to Exhibit 10.2 to the Form Exhibit 10.2 26 March, 2024 Peter Sorensen 17105 Hampton Ct Minnetonka, MN 55345 [email protected] Dear Peter: SANUWAVE, Inc. (the “Company”) is pleased to extend to you this conditional offer of employment as Chief Financial Officer reporting directly to Morgan Frank, CEO. Your position will be located at 11495 Valley View Rd Eden Prairie, MN 55344. We anticipate your start date will be on
April 1, 2024	EX-10.1	Separation and Release Agreement, dated March 29, 2024 (Incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on April 1, 2024). Exhibit 10.1 SEPARATION AND RELEASE AGREEMENT Background I. I Toni Rinow was employed by SANUWAVE (as defined below) until my employment was terminated effective March 28, 2024 (my "Separation Date"). II. SANUWAVE has offered to provide me certain Consideration (as defined below) subject to the terms and conditions of this Separation and Release Agreement ("Release"). III. It is my desire to accep
April 1, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 28, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File
April 1, 2024	EX-99.1	SANUWAVE Health Appoints Industry Veteran Peter Sorensen as Chief Financial Officer SANUWAVE Health, Inc. April 1, 2024 Sorensen brings strong finance, forecasting, analysis, and capital markets experience as well as abilities in software, process au Exhibit 99.1 SANUWAVE Health Appoints Industry Veteran Peter Sorensen as Chief Financial Officer SANUWAVE Health, Inc. April 1, 2024 Sorensen brings strong finance, forecasting, analysis, and capital markets experience as well as abilities in software, process automation, and human resources to Sanuwave. EDEN PRAIRIE, MN, April 1, 2024 (GLOBE NEWSWIRE) - via NewMediaWire – SANUWAVE Health, Inc. (t
March 22, 2024	EX-99.1	SANUWAVE Announces Record Q4 and FY2023 Revenue Exhibit 99.1 SANUWAVE Announces Record Q4 and FY2023 Revenue Q4 2023 revenues were a record $7.0 million, up 27% from Q4 2022 FY 2023 revenues were a record $20.4 million, up 22% from FY2022 Operating income was $1 million for Q4 2023 compared to an operating loss of $1.5 million for Q4 2022 Company provides guidance for revenue growth of 45-55% for Q1 2024 vs Q1 2023 and initiates annual guidance
March 22, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 22, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File
March 21, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to.
March 21, 2024	EX-21.1	List of Subsidiaries EXHIBIT 21.1 List of Subsidiaries Direct Subsidiary of SANUWAVE Health, Inc. 1. SANUWAVE, Inc., a Delaware corporation Subsidiaries of SANUWAVE, Inc. – Indirect Subsidiaries of SANUWAVE Health, Inc. 1. SANUWAVE Services, LLC, a Delaware limited liability company 1. SANUWAVE AG, a company organized under the laws of Switzerland
March 7, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 6, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File N
March 7, 2024	EX-10.1	Consent, Limited Waiver and Fifth Amendment to Note and Warrant Purchase and Security Agreement, dated as of March 6, 2024, by and among NH Expansion Credit Fund Holdings LP, as agent, the noteholders party thereto, and the Company (Incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on March 7, 2024). Exhibit 10.1 CONSENT, LIMITED WAIVER AND FIFTH AMENDMENT TO NOTE AND WARRANT PURCHASE AND SECURITY AGREEMENT This Consent, Limited Waiver and Fifth Amendment to Note and Warrant Purchase and Security Agreement (this “Amendment”) is entered into as of March 6, 2024, by and among NH EXPANSION CREDIT FUND HOLDINGS LP (“North Haven Expansion”), as agent (in such capacity, together with its successors
February 28, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission Fi
February 28, 2024	EX-2.1	Amendment Number One to Agreement and Plan of Merger, dated as of February 27, 2024, by and between SEP Acquisition Corp. and SANUWAVE Health, Inc. (Incorporated by reference to Exhibit 2.1 to the Form 8-K filed with the SEC on February 28, 2024). Exhibit 2.1 Execution Version AMENDMENT NUMBER ONE TO AGREEMENT AND PLAN OF MERGER THIS AMENDMENT NUMBER ONE TO AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated as of February 27, 2024, is by and between (i) SEP Acquisition Corp., a Delaware corporation (the “Purchaser”), and (ii) SANUWAVE Health, Inc., a Nevada corporation (the “Company”). RECITALS WHEREAS, Purchaser, SEP Acquisition Holdin
February 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission Fi
February 28, 2024	EX-2.1	AMENDMENT NUMBER ONE TO AGREEMENT AND PLAN OF MERGER Exhibit 2.1 Execution Version AMENDMENT NUMBER ONE TO AGREEMENT AND PLAN OF MERGER THIS AMENDMENT NUMBER ONE TO AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated as of February 27, 2024, is by and between (i) SEP Acquisition Corp., a Delaware corporation (the “Purchaser”), and (ii) SANUWAVE Health, Inc., a Nevada corporation (the “Company”). RECITALS WHEREAS, Purchaser, SEP Acquisition Holdin
February 23, 2024	425	Filed by Sanuwave Health, Inc. Filed by Sanuwave Health, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Sanuwave Health, Inc. Commission File No.: 000-52985 The following press release was released by Sanuwave Health, Inc. on February 22, 2024. Sanuwave Health Reports Stockholder Approval of SEPA Merger at Special Mee
February 21, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 21, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission Fi
February 21, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 false000141766300014176632024-02-212024-02-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 14, 2024	SC 13G/A	SNWV / SANUWAVE Health, Inc. / Opaleye Management Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Sanuwave Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 80303D107 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108 (Name, Address and Telephone Number of Person Author
January 25, 2024	EX-10.5	Form of Waiver Letter, dated January 21, 2024, by and among the Company and certain purchasers (Incorporated by reference to Exhibit 10.5 to the Form 8-K filed with the SEC on January 21, 2024). Exhibit 10.5 SANUWAVE HEALTH, INC. Waiver Letter The undersigned is the holder of certain securities of SANUWAVE Health, Inc. (the “Company”) issued on January 21, 2024, including a Future Advance Convertible Promissory Note (the “Note”) and Common Stock Purchase Warrants, one of which has an exercise price of $0.067 per share of the Company’s common stock, par value $0.001 per share (the “Common
January 25, 2024	EX-10.1	Securities Purchase Agreement, dated January 21, 2024, by and among the Company and the purchasers identified on the signature pages thereto (Incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on January 21, 2024). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 21, 2024, by and between SANUWAVE Health, Inc., a corporation organized under the laws of Nevada (the “Company”), and the purchasers identified on the signature pages hereto (including their successors and permitted assigns, the “Purchasers,” and each, a “Purchaser”). WHEREAS, su
January 25, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 21, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission Fil
January 25, 2024	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 21, 2024, by and between SANUWAVE Health, Inc., a corporation organized under the laws of Nevada (the “Company”), and the purchasers identified on the signature pages hereto (including their successors and permitted assigns, the “Purchasers,” and each, a “Purchaser”). WHEREAS, su
January 25, 2024	EX-10.2	SECURITY AGREEMENT Exhibit 10.2 SECURITY AGREEMENT THIS SECURITY AGREEMENT dated as of January 21, 2024 (this “Agreement”), is made by SANUWAVE Health, Inc., a corporation organized under the laws of Nevada (the “Borrower”), having an address of 11495 Valley View Road, Eden Prairie, MN 55344, in favor of the lenders set forth on the signature pages hereto (together with their successors and permitted assigns, the “L
January 25, 2024	EX-10.3	SUBORDINATION AGREEMENT Exhibit 10.3 SUBORDINATION AGREEMENT This SUBORDINATION AGREEMENT, dated as of January 21, 2024, is between NH EXPANSION CREDIT FUND HOLDINGS LP (“North Haven Expansion”), as agent for the Holders (as hereafter defined; in such capacity, together with its successors or permitted assigns, “Agent”), and the creditors set forth on the signature pages hereto (“Creditors”). R E C I T A L S A. SANUWAVE
January 25, 2024	EX-10.6	**** Exhibit 10.6 October [●], 2023 Greetings, We hope this communication finds you well. We are writing because you are a holder of certain outstanding Sanuwave notes issued in July 2023 and as you have likely seen Sanuwave has announced its intent to merge into a subsidiary of SEP Acquisition Corporation (SEPA) in order to become a Nasdaq traded company and as a means to restructure and simplify its
January 25, 2024	EX-4.2	COMMON STOCK PURCHASE WARRANT SANUWAVE HEALTH, INC. Exhibit 4.2 COMMON STOCK PURCHASE WARRANT SANUWAVE HEALTH, INC. Warrant Shares: [•] Initial Exercise Date: January 21, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [•] or [its/their] assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date h
January 25, 2024	EX-10.3	Subordination Agreement, dated January 21, 2024, by and among the Company, NH Expansion Credit Fund Holdings LP and certain creditors (Incorporated by reference to Exhibit 10.3 to the Form 8-K filed with the SEC on January 21, 2024). Exhibit 10.3 SUBORDINATION AGREEMENT This SUBORDINATION AGREEMENT, dated as of January 21, 2024, is between NH EXPANSION CREDIT FUND HOLDINGS LP (“North Haven Expansion”), as agent for the Holders (as hereafter defined; in such capacity, together with its successors or permitted assigns, “Agent”), and the creditors set forth on the signature pages hereto (“Creditors”). R E C I T A L S A. SANUWAVE
January 25, 2024	EX-4.2	COMMON STOCK PURCHASE WARRANT SANUWAVE HEALTH, INC. Exhibit 4.2 COMMON STOCK PURCHASE WARRANT SANUWAVE HEALTH, INC. Warrant Shares: [•] Initial Exercise Date: January 21, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [•] or [its/their] assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date h
January 25, 2024	EX-10.4	Registration Rights Agreement, dated January 21, 2024, by and among the Company and certain lenders (Incorporated by reference to Exhibit 10.4 to the Form 8-K filed with the SEC on January 21, 2024). Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of January 21, 2024 (the “Closing Date”), by and among SANUWAVE Health, Inc., a Nevada corporation (the “Company”), and each lender identified on the signature pages hereto (including their successors and assigns, the “Lenders,” and each, a “Lender”). RECITALS WHEREAS, the Company and the Le
January 25, 2024	EX-10.6	Form of Letter Agreement, dated January 21, 2024, by and among the Company and certain lenders (Incorporated by reference to Exhibit 10.6 to the Form 8-K filed with the SEC on January 21, 2024). Exhibit 10.6 October [●], 2023 Greetings, We hope this communication finds you well. We are writing because you are a holder of certain outstanding Sanuwave notes issued in July 2023 and as you have likely seen Sanuwave has announced its intent to merge into a subsidiary of SEP Acquisition Corporation (SEPA) in order to become a Nasdaq traded company and as a means to restructure and simplify its
January 25, 2024	EX-4.1	SANUWAVE HEALTH, INC. FUTURE ADVANCE CONVERTIBLE PROMISSORY NOTE Exhibit 4.1 THE INDEBTEDNESS EVIDENCED BY THIS NOTE (AS DEFINED BELOW) IS SUBORDINATE TO THE INDEBTEDNESS OF SANUWAVE HEALTH, INC. (OR ANY SUCCESSOR THERETO) TO NH EXPANSION CREDIT FUND HOLDINGS LP, TO THE EXTENT AND PURSUANT TO THE TERMS OF THAT CERTAIN SUBORDINATION AGREEMENT, DATED AS OF JANUARY 21, 2024, BY AND AMONG NH EXPANSION CREDIT FUND HOLDINGS LP AND THE PARTIES IDENTIFIED ON THE SIGNAT
January 25, 2024	EX-4.1	SANUWAVE HEALTH, INC. FUTURE ADVANCE CONVERTIBLE PROMISSORY NOTE Exhibit 4.1 THE INDEBTEDNESS EVIDENCED BY THIS NOTE (AS DEFINED BELOW) IS SUBORDINATE TO THE INDEBTEDNESS OF SANUWAVE HEALTH, INC. (OR ANY SUCCESSOR THERETO) TO NH EXPANSION CREDIT FUND HOLDINGS LP, TO THE EXTENT AND PURSUANT TO THE TERMS OF THAT CERTAIN SUBORDINATION AGREEMENT, DATED AS OF JANUARY 21, 2024, BY AND AMONG NH EXPANSION CREDIT FUND HOLDINGS LP AND THE PARTIES IDENTIFIED ON THE SIGNAT
January 25, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 21, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission Fil
January 25, 2024	EX-10.2	Security Agreement, dated January 21, 2024, by and among the Company and certain lenders (Incorporated by reference to Exhibit 10.2 to the Form 8-K filed with the SEC on January 21, 2024). Exhibit 10.2 SECURITY AGREEMENT THIS SECURITY AGREEMENT dated as of January 21, 2024 (this “Agreement”), is made by SANUWAVE Health, Inc., a corporation organized under the laws of Nevada (the “Borrower”), having an address of 11495 Valley View Road, Eden Prairie, MN 55344, in favor of the lenders set forth on the signature pages hereto (together with their successors and permitted assigns, the “L
January 25, 2024	EX-10.5	SANUWAVE HEALTH, INC. Waiver Letter Exhibit 10.5 SANUWAVE HEALTH, INC. Waiver Letter The undersigned is the holder of certain securities of SANUWAVE Health, Inc. (the “Company”) issued on January 21, 2024, including a Future Advance Convertible Promissory Note (the “Note”) and Common Stock Purchase Warrants, one of which has an exercise price of $0.067 per share of the Company’s common stock, par value $0.001 per share (the “Common
January 25, 2024	EX-10.4	REGISTRATION RIGHTS AGREEMENT Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of January 21, 2024 (the “Closing Date”), by and among SANUWAVE Health, Inc., a Nevada corporation (the “Company”), and each lender identified on the signature pages hereto (including their successors and assigns, the “Lenders,” and each, a “Lender”). RECITALS WHEREAS, the Company and the Le
January 22, 2024	425	Filed by Sanuwave Health, Inc. Filed by Sanuwave Health, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Sanuwave Health, Inc. Commission File No.: 000-52985 The following press release was released by Sanuwave Health, Inc. on January 22, 2024. Sanuwave Announces Special Meeting of Stockholders to Vote on Business Comb
January 22, 2024	DEFM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission only (as pe
January 12, 2024	PREM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☑ Preliminary Proxy Statement ☐ Confidential, for use of the Commission only (as perm
January 12, 2024	SC 13D/A	SNWV / SANUWAVE Health, Inc. / MANCHESTER MANAGEMENT CO LLC Activist Investment SC 13D/A 1 d1093621013d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 8)* Sanuwave Health, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 80303D107 (CUSIP Number) James E. Besser c/o Manchester Management Company, LLC 2 Calle Candina, #1701 San Juan, Puerto Rico, 00907
January 12, 2024	EX-FILING FEES	CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) SANUWAVE Health, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) SANUWAVE Health, Inc.
January 10, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 10, 2024 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission Fil
January 10, 2024	EX-99.1	SANUWAVE Health Announces Preliminary Revenue Results for the Fourth Quarter and Fiscal Year 2023, Ended December 31, 2023 Exhibit 99.1 SANUWAVE Health Announces Preliminary Revenue Results for the Fourth Quarter and Fiscal Year 2023, Ended December 31, 2023 SANUWAVE is pleased to announce preliminary revenues of $6.6 million to $6.8 million for the fourth quarter ended December 31, 2023. This represents a new quarterly revenue record for the Company. Q4 2023 revenue increased 20% to 24% over Q4 2022 and in excess of
January 4, 2024	SC 13D/A	SNWV / SANUWAVE Health, Inc. / MANCHESTER MANAGEMENT CO LLC Activist Investment SC 13D/A 1 d1092600013d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7)* Sanuwave Health, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 80303D107 (CUSIP Number) James E. Besser c/o Manchester Management Company, LLC 2 Calle Candina, #1701 San Juan, Puerto Rico, 00907
January 3, 2024	EX-10.4	REGISTRATION RIGHTS AGREEMENT Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of December 30, 2023 (the “Closing Date”), by and among SANUWAVE Health, Inc., a Nevada corporation (the “Company”), and each lender identified on the signature pages hereto (including their successors and assigns, the “Lenders,” and each, a “Lender”). RECITALS WHEREAS, the Company and the L
January 3, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 30, 2023 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission Fi
January 3, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 30, 2023 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission Fi
January 3, 2024	EX-10.6	**** Exhibit 10.6 December [•], 2023 Greetings, We hope this communication finds you well. We are writing because you are a holder of certain outstanding Sanuwave notes and warrants issued in December 2023 and as you have likely seen Sanuwave has announced its intent to merge into a subsidiary of SEP Acquisition Corporation (SEPA) in order to become a Nasdaq traded company and as a means to restructure
January 3, 2024	EX-10.6	**** Exhibit 10.6 December [•], 2023 Greetings, We hope this communication finds you well. We are writing because you are a holder of certain outstanding Sanuwave notes and warrants issued in December 2023 and as you have likely seen Sanuwave has announced its intent to merge into a subsidiary of SEP Acquisition Corporation (SEPA) in order to become a Nasdaq traded company and as a means to restructure
January 3, 2024	EX-10.3	SUBORDINATION AGREEMENT Exhibit 10.3 SUBORDINATION AGREEMENT This SUBORDINATION AGREEMENT, dated as of December 30, 2023, is between NH EXPANSION CREDIT FUND HOLDINGS LP (“North Haven Expansion”), as agent for the Holders (as hereafter defined; in such capacity, together with its successors or permitted assigns, “Agent”), and the creditors set forth on the signature pages hereto (“Creditors”). R E C I T A L S A. SANUWAVE
January 3, 2024	EX-10.1	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 30, 2023, by and between SANUWAVE Health, Inc., a corporation organized under the laws of Nevada (the “Company”), and the purchasers identified on the signature pages hereto (including their successors and permitted assigns, the “Purchasers,” and each, a “Purchaser”). WHEREAS, s
January 3, 2024	EX-10.2	SECURITY AGREEMENT Exhibit 10.2 SECURITY AGREEMENT THIS SECURITY AGREEMENT dated as of December 30, 2023 (this “Agreement”), is made by SANUWAVE Health, Inc., a corporation organized under the laws of Nevada (the “Borrower”), having an address of 11495 Valley View Road, Eden Prairie, MN 55344, in favor of the lenders set forth on the signature pages hereto (together with their successors and permitted assigns, the “
January 3, 2024	EX-4.2	COMMON STOCK PURCHASE WARRANT SANUWAVE HEALTH, INC. Exhibit 4.2 COMMON STOCK PURCHASE WARRANT SANUWAVE HEALTH, INC. Warrant Shares: [•] Initial Exercise Date: December 30, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [•] or [its/their] assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date
January 3, 2024	EX-10.5	SANUWAVE HEALTH, INC. Waiver Letter Exhibit 10.5 SANUWAVE HEALTH, INC. Waiver Letter The undersigned is the holder of certain securities of SANUWAVE Health, Inc. (the “Company”) issued on December 30, 2023, including a Future Advance Convertible Promissory Note (the “Note”) and Common Stock Purchase Warrants, one of which has an exercise price of $0.067 per share of the Company’s common stock, par value $0.001 per share (the “Common
January 3, 2024	EX-4.2	COMMON STOCK PURCHASE WARRANT SANUWAVE HEALTH, INC. Exhibit 4.2 COMMON STOCK PURCHASE WARRANT SANUWAVE HEALTH, INC. Warrant Shares: [•] Initial Exercise Date: December 30, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [•] or [its/their] assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date
January 3, 2024	EX-4.1	SANUWAVE HEALTH, INC. FUTURE ADVANCE CONVERTIBLE PROMISSORY NOTE Exhibit 4.1 THE INDEBTEDNESS EVIDENCED BY THIS NOTE (AS DEFINED BELOW) IS SUBORDINATE TO THE INDEBTEDNESS OF SANUWAVE HEALTH, INC. (OR ANY SUCCESSOR THERETO) TO NH EXPANSION CREDIT FUND HOLDINGS LP, TO THE EXTENT AND PURSUANT TO THE TERMS OF THAT CERTAIN SUBORDINATION AGREEMENT, DATED AS OF DECEMBER 30, 2023, BY AND AMONG NH EXPANSION CREDIT FUND HOLDINGS LP AND THE PARTIES IDENTIFIED ON THE SIGNA
January 3, 2024	EX-4.1	SANUWAVE HEALTH, INC. FUTURE ADVANCE CONVERTIBLE PROMISSORY NOTE Exhibit 4.1 THE INDEBTEDNESS EVIDENCED BY THIS NOTE (AS DEFINED BELOW) IS SUBORDINATE TO THE INDEBTEDNESS OF SANUWAVE HEALTH, INC. (OR ANY SUCCESSOR THERETO) TO NH EXPANSION CREDIT FUND HOLDINGS LP, TO THE EXTENT AND PURSUANT TO THE TERMS OF THAT CERTAIN SUBORDINATION AGREEMENT, DATED AS OF DECEMBER 30, 2023, BY AND AMONG NH EXPANSION CREDIT FUND HOLDINGS LP AND THE PARTIES IDENTIFIED ON THE SIGNA
January 3, 2024	EX-10.4	Registration Rights Agreement, dated December 30, 2023, by and among the Company and certain lenders (Incorporated by reference to Exhibit 10.4 to the Form 8-K filed with the SEC on January 3, 2024). Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of December 30, 2023 (the “Closing Date”), by and among SANUWAVE Health, Inc., a Nevada corporation (the “Company”), and each lender identified on the signature pages hereto (including their successors and assigns, the “Lenders,” and each, a “Lender”). RECITALS WHEREAS, the Company and the L
January 3, 2024	EX-10.5	Form of Waiver Letter with Purchasers in December 2023 offering (Incorporated by reference to Exhibit 10.5 to the Form 8-K filed with the SEC on January 3, 2024). Exhibit 10.5 SANUWAVE HEALTH, INC. Waiver Letter The undersigned is the holder of certain securities of SANUWAVE Health, Inc. (the “Company”) issued on December 30, 2023, including a Future Advance Convertible Promissory Note (the “Note”) and Common Stock Purchase Warrants, one of which has an exercise price of $0.067 per share of the Company’s common stock, par value $0.001 per share (the “Common
January 3, 2024	EX-10.2	SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 30, 2023, by and between SANUWAVE Health, Inc., a corporation organized under the laws of Nevada (the “Company”), and the purchasers identified on the signature pages hereto (including their successors and permitted assigns, the “Purchasers,” and each, a “Purchaser”). WHEREAS, s
January 3, 2024	EX-10.3	SUBORDINATION AGREEMENT Exhibit 10.3 SUBORDINATION AGREEMENT This SUBORDINATION AGREEMENT, dated as of December 30, 2023, is between NH EXPANSION CREDIT FUND HOLDINGS LP (“North Haven Expansion”), as agent for the Holders (as hereafter defined; in such capacity, together with its successors or permitted assigns, “Agent”), and the creditors set forth on the signature pages hereto (“Creditors”). R E C I T A L S A. SANUWAVE
January 3, 2024	EX-10.2	SECURITY AGREEMENT Exhibit 10.2 SECURITY AGREEMENT THIS SECURITY AGREEMENT dated as of December 30, 2023 (this “Agreement”), is made by SANUWAVE Health, Inc., a corporation organized under the laws of Nevada (the “Borrower”), having an address of 11495 Valley View Road, Eden Prairie, MN 55344, in favor of the lenders set forth on the signature pages hereto (together with their successors and permitted assigns, the “
November 22, 2023	SC 13D/A	SNWV / Sanuwave Health Inc / MANCHESTER MANAGEMENT CO LLC Activist Investment SC 13D/A 1 d1088171613d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6)* Sanuwave Health, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 80303D107 (CUSIP Number) James E. Besser c/o Manchester Management Company, LLC 2 Calle Candina, #1701 San Juan, Puerto Rico, 00907
November 13, 2023	EX-99.1	SANUWAVE Announces Q3 2023 Financial Results Exhibit 99.1 SANUWAVE Announces Q3 2023 Financial Results EDEN PRAIRIE, MN, NOVEMBER 10, 2023 – SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced its 3rd quarter 2023 results. For the three months ended September 30, 2023: ■ Revenue for the three months ended September 30, 2023 totaled $5.0 mil
November 13, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 10, 2023 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission Fi
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-52985 SANUWAVE
October 12, 2023	425	**** Filed by SANUWAVE Health, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: SANUWAVE Health, Inc. Commission File No.: 000-52985 The following letter is being sent to holders of certain outstanding warrants issued by SANUWAVE Health, Inc. in August 2022: October [●], 2023 Greetings, We hope
October 10, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 10, 2023 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission Fil
October 10, 2023	EX-99.1	SANUWAVE Health Announces Preliminary Revenue Results for the Third Quarter Ended September 30, 2023 Exhibit 99.1 SANUWAVE Health Announces Preliminary Revenue Results for the Third Quarter Ended September 30, 2023 SANUWAVE is pleased to announce preliminary revenues of $4.7 million to $4.9 million for the third quarter ended September 30, 2023 Results indicate 13-18% growth rate over Q3 2022 UltraMist revenues (systems and consumables) increased in excess of 25% year on year and by greater than
September 29, 2023	CORRESP	SANUWAVE Health, Inc. 11495 Valley View Road Eden Prairie, Minnesota 55344 SANUWAVE Health, Inc. 11495 Valley View Road Eden Prairie, Minnesota 55344 September 29, 2023 VIA EDGAR TRANSMISSION Division of Corporation Finance Office of Industrial Applications and Services United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jessica Ansart Katherine Bagley Re: SANUWAVE Health, Inc. Registration Statement on Form S-1 (Registra
September 29, 2023	S-1/A	As filed with the Securities and Exchange Commission on September 29, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 29, 2023 Registration No.
September 25, 2023	EX-99.1	Investor Presentation September 2023 2 This presentation (“Presentation”) is for informational purposes only to assist interested parties in making an evaluation with respect to a proposed business combination and related transactions (collectively, Exhibit 99.1 Investor Presentation September 2023 2 This presentation (“Presentation”) is for informational purposes only to assist interested parties in making an evaluation with respect to a proposed business combination and related transactions (collectively, the “Business Combination”) between SEP Acquisition Corp. (“SEPA”) and SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”). This Presenta
September 25, 2023	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 25, 2023 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission F
September 25, 2023	EX-99.1	Investor Presentation September 2023 This presentation (“Presentation”) is for informational purposes only to assist interested parties in making an evaluation with respect to a proposed business combination and related transactions (collectively, th Exhibit 99.1 Investor Presentation September 2023 This presentation (“Presentation”) is for informational purposes only to assist interested parties in making an evaluation with respect to a proposed business combination and related transactions (collectively, the “Business Combination”) between SEP Acquisition Corp. (“SEPA”) and SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”). This Presentati
September 25, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 25, 2023 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission F
August 24, 2023	425	Filed by SANUWAVE Health, Inc. Filed by SANUWAVE Health, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: SANUWAVE Health, Inc. Commission File No.: 000-52985 The following is a transcript of a conference call held by SANUWAVE Health, Inc. on August 24, 2023 at 8:30 a.m. EDT. Morgan C. Frank, Chairman and Chief Executiv
August 23, 2023	EX-2.1	AGREEMENT AND PLAN OF MERGER by and among SEP ACQUISITION CORP., as the Purchaser, SEP ACQUISITION HOLDINGS INC., as Merger Sub, SANUWAVE HEALTH, INC., as the Company Dated as of August 23, 2023 TABLE OF CONTENTS Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among SEP ACQUISITION CORP., as the Purchaser, SEP ACQUISITION HOLDINGS INC., as Merger Sub, and SANUWAVE HEALTH, INC., as the Company Dated as of August 23, 2023 TABLE OF CONTENTS Page ARTICLE I MERGER 3 1.1 Merger 3 1.2 Effective Time 3 1.3 Effect of the Merger 3 1.4 Tax Treatment 3 1.5 Articles of Incorporation and Bylaws 3 1.6 D
August 23, 2023	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 23, 2023 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File
August 23, 2023	EX-10.1	FORM OF VOTING AGREEMENT Exhibit 10.1 Final Form FORM OF VOTING AGREEMENT This Voting Agreement (this “Agreement”) is made as of August [●], 2023, by and among (i) SEP Acquisition Corp., a Delaware corporation (the “Purchaser”), (ii) SANUWAVE Health, Inc., a Nevada corporation (the “Company”), and (iii) the undersigned holder (“Holder”) of capital stock and/or securities convertible into capital stock of the Company. Any
August 23, 2023	EX-10.3	LOCK-UP AGREEMENT Exhibit 10.3 LOCK-UP AGREEMENT (Company) This Lock-Up Agreement (this “Agreement”) is made and entered into as of August [●], 2023 by and among (i) SEP Acquisition Corp., a Delaware corporation (the “Purchaser”), and (ii) the undersigned (“Holder”). Any capitalized term used but not defined in this Agreement will have the meaning ascribed to such term in the Merger Agreement. WHEREAS, on the date
August 23, 2023	SC 13D/A	SNWV / Sanuwave Health Inc / MANCHESTER MANAGEMENT CO LLC Activist Investment SC 13D/A 1 d1079519913d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5)* Sanuwave Health, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 80303D107 (CUSIP Number) James E. Besser c/o Manchester Management Company, LLC 2 Calle Candina, #1701 San Juan, Puerto Rico, 00907
August 23, 2023	EX-10.2	SPONSOR VOTING AGREEMENT Exhibit 10.2 SPONSOR VOTING AGREEMENT This Voting Agreement (this “Agreement”) is made as of August 23, 2023, by and among (i) Mercury Sponsor Group I LLC, a Delaware limited liability company (the “Sponsor”), (ii) SEP Acquisition Corp., a Delaware corporation (the “Purchaser”), and (iii) SANUWAVE Health, Inc., a Nevada corporation (the “Company”). Any capitalized term used but not defined in this
August 23, 2023	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 23, 2023 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File
August 23, 2023	EX-99.1	SANUWAVE Health, Inc., a Leading Provider of FDA Approved Next-Generation Wound Care Products, Enters into a Merger Agreement with Sweat Equity Partners and Mercury Life Sciences-affiliated SEP Acquisition Corp., a Nasdaq-Listed Company Exhibit 99.1 SANUWAVE Health, Inc., a Leading Provider of FDA Approved Next-Generation Wound Care Products, Enters into a Merger Agreement with Sweat Equity Partners and Mercury Life Sciences-affiliated SEP Acquisition Corp., a Nasdaq-Listed Company • SANUWAVE Health Inc. (OTCQB: SNWV) has entered into a definitive merger agreement with SEP Acquisition Corp. (Nasdaq: SEPA). Upon closing, the combi
August 11, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2023 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File
August 11, 2023	EX-99.1	SANUWAVE Announces Q2 2023 Financial Results Exhibit 99.1 SANUWAVE Announces Q2 2023 Financial Results EDEN PRAIRIE, MN, AUGUST 11, 2023 – SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced its 2nd quarter 2023 results. For the three months ended June 30, 2023: ■ Revenue for the three months ended June 30, 2023 totaled $4.7 million, an inc
August 10, 2023	SC 13D/A	SNWV / Sanuwave Health Inc / MANCHESTER MANAGEMENT CO LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
August 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-52985 SANUWAVE Healt
July 31, 2023	EX-10.1	Offer Letter, dated July 20, 2023, by and between the Company and Andrew Walko (Incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on July 31, 2023). Exhibit 10.1 July, 18 2023 Dear Andrew, SANUWAVE, Inc. ("Company") is pleased to offer you the position of President Your start date will be (TBD). We are confident that your acceptance marks the beginning of a challenging and mutually beneficial relationship. This written offer will expire on M onday1 July 241 2023, at midnight eastern standard time, if not accepted by you before that time. Accep
July 31, 2023	EX-99	Walko brings 17 years of Manufacturing, Production, Operations, and Logistics Experience, most recently as President of Biomerics, where he led a 170-person contract manufacturing organization Exhibit 99.1 SANUWAVE Health Appoints Industry Veteran Andrew Walko as President SANUWAVE Health, Inc. July 31, 2023 Walko brings 17 years of Manufacturing, Production, Operations, and Logistics Experience, most recently as President of Biomerics, where he led a 170-person contract manufacturing organization EDEN PRAIRIE, MN, July 31, 2023 (GLOBE NEWSWIRE) - via NewMediaWire – SANUWAVE Health, Inc
July 31, 2023	EX-10.2	Non-Compete and Confidentiality Agreement, dated July 31, 2023, by and between the Company and Andrew Walko (Incorporated by reference to Exhibit 10.2 to the Form 8-K filed with the SEC on July 31, 2023). Exhibit 10.2 Non- Compete and Confidentiality Agreement In consideration of my employment or continued employment by SANUWAVE Health, Inc. (the "Company"), the Company's disclosure of certain Proprietary Information (as defined below) to me, any compensation now and/or hereafter paid to me, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
July 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 31, 2023 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File N
July 27, 2023	SC 13D/A	SNWV / Sanuwave Health Inc / MANCHESTER MANAGEMENT CO LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
July 26, 2023	EX-10.2	Subordination Agreement, dated July 21, 2023, by and among the Company, NH Expansion Credit Fund Holdings LP and certain creditors (Incorporated by reference to Exhibit 10.2 to the Form 8-K filed with the SEC on July 26, 2023). Exhibit 10.2 SUBORDINATION AGREEMENT This SUBORDINATION AGREEMENT, dated as of July 21, 2023, is between NH EXPANSION CREDIT FUND HOLDINGS LP (“North Haven Expansion”), as agent for the Holders (as hereafter defined; in such capacity, together with its successors or permitted assigns, “Agent”), and the creditors set forth on the signature pages hereto (“Creditors”). R E C I T A L S A. SANUWAVE HEA
July 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 21, 2023 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File N
July 26, 2023	EX-10.1	Security Agreement, dated July 21, 2023, by and among the Company and certain lenders (Incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on July 26, 2023). Exhibit 10.1 SECURITY AGREEMENT THIS SECURITY AGREEMENT dated as of July 21, 2023 (this “Agreement”), is made by SANUWAVE Health, Inc., a corporation organized under the laws of Nevada (the “Borrower”), having an address of 11495 Valley View Road, Eden Prairie, MN 55344, in favor of the lenders set forth on the signature pages hereto (together with their successors and permitted assigns, the “Lend
July 26, 2023	EX-4.1	ASSET-BACKED SECURED PROMISSORY NOTE Exhibit 4.1 ASSET-BACKED SECURED PROMISSORY NOTE THE INDEBTEDNESS EVIDENCED BY THIS NOTE IS SUBORDINATE TO THE INDEBTEDNESS OF SANUWAVE HEALTH, INC. (OR ANY SUCCESSOR THERETO) TO NH EXPANSION CREDIT FUND HOLDINGS LP, TO THE EXTENT AND PURSUANT TO THE TERMS OF THAT CERTAIN SUBORDINATION AGREEMENT, DATED AS OF JULY 21, 2023, BY AND AMONG NH EXPANSION CREDIT FUND HOLDINGS LP AND THE PARTIES IDENTIFIE
July 26, 2023	CORRESP	Faegre Drinker Biddle & Reath Faegre Drinker Biddle & Reath LLP 2200 Wells Fargo Center 90 S. Seventh Street Minneapolis, Minnesota 55402 +1 612 766 7000 main +1 612 766 1600 fax By EDGAR July 26, 2023 Jessica Ansart Katherine Bagley U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, NE Washington, DC 20549 Re: SANUWAVE Health, Inc. Registration
July 26, 2023	EX-10.3	[Signature page follows] Exhibit 10.3 July 21, 2023 SANUWAVE Health, Inc. 11495 Valley View Road Eden Prairie, MN 55344 Attention: Morgan Frank Re: Asset-Backed Secured Promissory Note Mr. Frank: We refer to those certain Asset-Backed Secured Promissory Notes, dated as of July 21, 2023 (the “Notes”), made by and between (i) SANUWAVE Health, Inc., a corporation incorporated under the laws of the State of Nevada (the “Compa
July 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 17, 2023 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File N
July 19, 2023	EX-99.1	SANUWAVE is pleased to announce preliminary revenues of $4.5 million to $4.7 million for Q2 ended June 30, 2023 Results indicate 16-21% growth rate over Q2 2022, consistent with guidance provided in the Q1 2023 earnings release. Exhibit 99.1 SANUWAVE Health Announces Preliminary Revenue Results for the Second Quarter Ended June 30, 2023 SANUWAVE Health, Inc. July 17, 2023 SANUWAVE is pleased to announce preliminary revenues of $4.5 million to $4.7 million for Q2 ended June 30, 2023 Results indicate 16-21% growth rate over Q2 2022, consistent with guidance provided in the Q1 2023 earnings release. EDEN PRAIRIE, MN, July 17
June 30, 2023	EX-10.75	Registration Rights Agreement, dated May 9, 2023, by and among the Company and certain lenders. Exhibit 10.75 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of May 9, 2023 (the “Closing Date”), by and among SANUWAVE Health, Inc., a Nevada corporation (the “Company”), and each lender identified on the signature pages hereto (including their successors and assigns, the “Lenders,” and each, a “Lender”). RECITALS WHEREAS, the Company and the Lender
June 30, 2023	EX-FILING FEES	Calculation of Filing Fee Tables Form S-1 (Form Type) SANUWAVE Health, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) SANUWAVE Health, Inc.
June 30, 2023	EX-4.1	SANUWAVE HEALTH, INC. FUTURE ADVANCE CONVERTIBLE PROMISSORY NOTE Exhibit 4.1 THE INDEBTEDNESS EVIDENCED BY THIS NOTE (AS DEFINED BELOW) IS SUBORDINATE TO THE INDEBTEDNESS OF SANUWAVE HEALTH, INC. (OR ANY SUCCESSOR THERETO) TO NH EXPANSION CREDIT FUND HOLDINGS LP, TO THE EXTENT AND PURSUANT TO THE TERMS OF THAT CERTAIN SUBORDINATION AGREEMENT, DATED AS OF MAY 9, 2023, BY AND AMONG NH EXPANSION CREDIT FUND HOLDINGS LP AND THE PARTIES IDENTIFIED ON THE SIGNATURE P
June 30, 2023	EX-4.2	COMMON STOCK PURCHASE WARRANT SANUWAVE HEALTH, INC. Exhibit 4.2 COMMON STOCK PURCHASE WARRANT SANUWAVE HEALTH, INC. Warrant Shares: [●] Initial Exercise Date: May 9, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “I
June 30, 2023	S-1	As filed with the Securities and Exchange Commission on June 30, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 30, 2023 Registration No.
June 30, 2023	EX-10.74	SECURITY AGREEMENT Exhibit 10.74 SECURITY AGREEMENT THIS SECURITY AGREEMENT dated as of May 9, 2023 (this “Agreement”), is made by SANUWAVE Health, Inc., a corporation organized under the laws of Nevada (the “Borrower”), having an address of 11495 Valley View Road, Eden Prairie, MN 55344, in favor of the lenders set forth on the signature pages hereto (together with their successors and permitted assigns, the “Lende
June 30, 2023	EX-10.72	SECURITIES PURCHASE AGREEMENT Exhibit 10.72 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 9, 2023, by and between SANUWAVE Health, Inc., a corporation organized under the laws of Nevada (the “Company”), and the purchasers identified on the signature pages hereto (including their successors and permitted assigns, the “Purchasers,” and each, a “Purchaser”). WHEREAS, subjec
June 30, 2023	EX-10.73	SUBORDINATION AGREEMENT Exhibit 10.73 SUBORDINATION AGREEMENT This SUBORDINATION AGREEMENT, dated as of May 9, 2023, is between NH EXPANSION CREDIT FUND HOLDINGS LP (“North Haven Expansion”), as agent for the Holders (as hereafter defined; in such capacity, together with its successors or permitted assigns, “Agent”), and the creditors set forth on the signature pages hereto (“Creditors”). R E C I T A L S A. SANUWAVE HEAL
June 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 23, 2023 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File N
June 29, 2023	EX-10.1	Fourth Amendment to Note and Warrant Purchase and Security Agreement, dated June 23, 2023, by and among the Company, the noteholder party thereto and NH Expansion Credit Fund Holdings LP, as agent (Incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on June 29, 2023). Exhibit 10.1 FOURTH AMENDMENT TO NOTE AND WARRANT PURCHASE AND SECURITY AGREEMENT This Fourth Amendment to Note and Warrant Purchase and Security Agreement (this “Amendment”) is entered into as of June 23, 2023, by and among NH EXPANSION CREDIT FUND HOLDINGS LP (“North Haven Expansion”), as agent (in such capacity, together with its successors or permitted assigns, “Agent”), the Holders from time
May 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 23, 2023 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File Nu
May 30, 2023	EX-99.1	SANUWAVE Health, Inc. Appoints Morgan Frank as Chief Executive Officer Exhibit 99.1 SANUWAVE Health, Inc. Appoints Morgan Frank as Chief Executive Officer Published: May 24, 2023 Frank brings 29 years of experience in life sciences, technology, and capital markets. Kevin Richardson to remain at SANUWAVE as Chief Strategic Officer and as a member of the Board of Directors. Eden Prairie, MN / May 24, 2023/ SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB:SNWV
May 30, 2023	EX-10.1	Executive Employment Agreement, effective May 23, 2023, by and between the Company and Morgan Frank (Incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on May 30, 2023). Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (“Agreement”) is effective as of May 23, 2023 (the “Effective Date”), by and between SANUWAVE Health, Inc., a Nevada corporation (the “Company”), and Morgan Frank (the “Executive”). RECITALS WHEREAS, the Company desires to employ Executive and Executive desires to accept engagement by the Company as its Chief Executive
May 30, 2023	EX-10.2	TRANSITION AND SEPARATION AGREEMENT Exhibit 10.2 TRANSITION AND SEPARATION AGREEMENT This Transition and Separation Agreement (“Agreement”) is entered into by and between Kevin Richardson, II (“Employee”) and SANUWAVE Health, Inc. (the “Company”), effective as of May 23, 2023 (“Effective Date”). RECITALS A. Employee has been employed by the Company as its Chief Executive Officer. B. Employee and the Company have agreed to conclude t
May 16, 2023	SC 13D/A	SNWV / Sanuwave Health Inc / MANCHESTER MANAGEMENT CO LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
May 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 12, 2023 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File Nu
May 12, 2023	EX-99.1	Sanuwave announces Q1 2023 financial results Exhibit 99.1 Sanuwave announces Q1 2023 financial results SANUWAVE Health, Inc. EDEN PRAIRIE, MN, May 12, 2023 SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced 1st quarter 2023 results. For the three-months ended March 31, 2023: • Revenues increased 18% to $3.8 million for Q1 2023 versus $3.2 million for the same period la
May 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-52985 SANUWAVE Heal
April 3, 2023	EX-99.1	SANUWAVE Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update EX-99.1 2 brhc10050787ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE SANUWAVE Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update EDEN PRARIE, MN, April 3, 2023 (GLOBE NEWSWIRE) - via NewMediaWire – SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today reported financial results for the fourth qu
April 3, 2023	8-K	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 3, 2023 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File N
March 31, 2023	8-K	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 28, 2023 SANUWAVE Health, Inc. (Exact name of registrant as specified in its charter) Nevada 000-52985 20-1176000 (State or other jurisdiction of incorporation) (Commission File
March 31, 2023	EX-21.1	List of Subsidiaries EX-21.1 2 brhc10050349ex21-1.htm EXHIBIT 21.1 EXHIBIT 21.1 List of Subsidiaries Direct Subsidiary of SANUWAVE Health, Inc. 1. SANUWAVE, Inc., a Delaware corporation Subsidiaries of SANUWAVE, Inc. – Indirect Subsidiaries of SANUWAVE Health, Inc. 1. SANUWAVE Services, LLC, a Delaware limited liability company 1. SANUWAVE AG, a company organized under the laws of Switzerland
March 31, 2023	10-K	Item 13. Certain Relationships and Related Transactions, and Directors Independence—Related Party Transactions UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to.
February 13, 2023	SC 13G/A	SNWV / SANUWAVE Health, Inc. / Opaleye Management Inc. Passive Investment SC 13G/A 1 sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Sanuwave Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 80303D107 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108 (Name, Address and Telephone N
January 31, 2023	CORRESP	Faegre Drinker Biddle & Reath LLP CORRESP 1 filename1.htm faegredrinker.com Faegre Drinker Biddle & Reath LLP 2200 Wells Fargo Center 90 S. Seventh Street Minneapolis, Minnesota 55402 +1 612 766 7000 main +1 612 766 1600 fax By EDGAR January 31, 2023 Benjamin Richie Jane Park U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, NE Washington, DC 20549
January 31, 2023	CORRESP	SANUWAVE Health, Inc. 11495 Valley View Road Eden Prairie, Minnesota 55344 SANUWAVE Health, Inc. 11495 Valley View Road Eden Prairie, Minnesota 55344 January 31, 2023 VIA EDGAR TRANSMISSION Division of Corporation Finance Office of Industrial Applications and Services United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Benjamin Richie Jane Park Re: SANUWAVE Health, Inc. Registration Statement on Form S-1 (Registration No.
January 31, 2023	S-1/A	As filed with the Securities and Exchange Commission on January 31, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 31, 2023 Registration No.
January 31, 2023	EX-3.12	Certificate of Amendment of the Articles of Incorporation, dated January 31, 2023 (Incorporated by reference to Exhibit 3.12 to the Form S-1/A filed with the SEC on January 31, 2023). Exhibit 3.12
January 13, 2023	SC 13D/A	SNWV / SANUWAVE Health, Inc. / MANCHESTER MANAGEMENT CO LLC Activist Investment SC 13D/A 1 d991115013d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Sanuwave Health, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 80303D107 (CUSIP Number) James E. Besser c/o Manchester Management Company, LLC 2 Calle Candina, #1701 San Juan, Puerto Rico, 00907
December 22, 2022	EX-10.70	Registration Rights Agreement, dated November 14, 2022, by and among the Company and certain lenders (Incorporated by reference to Exhibit 10.70 to the Form S-1/A filed with the SEC on January 31, 2023). Exhibit 10.70 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made as of November 14, 2022 (the ?Closing Date?), by and among SANUWAVE Health, Inc., a Nevada corporation (the ?Company?), and each lender identified on the signature pages hereto (including their successors and assigns, the ?Lenders,? and each, a ?Lender?). RECITALS WHEREAS, the Company and the
December 22, 2022	S-1/A	As filed with the Securities and Exchange Commission on December 21, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 21, 2022 Registration No.

SNWV / SANUWAVE Health, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)